Of the many ARBs, telmisartan may be more effective in lowering the risk of diabetes and differs from other ARBs since it is structurally similar to pioglitazone and can activate PPARγ, even at low concentrations.[10] Meta-analysis of 21 randomized clinical trials showed the effect of improving insulin resistance compared to telmisartan and other ARBs.[28] A previous study showed that the combination of rosuvastatin with telmisartan significantly decreased HOMA-IR in patients with IFG compared to irbesartan or olmesartan.[11]. The gene discussed is PPARG; the disease is diabetes mellitus.